Non-hodgkin Lymphoma,B Cell Clinical Trial
Official title:
A Phase I/II Clinical Study of the Safety and Efficacy of CD19-targeted Non-viral PD1 Site-specific Integrated CAR-T Cell Injection (BRL-201) in the Treatment of Relapsed or Refractory B Lymphocyte Non-Hodgkin Lymphoma
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects. Based on the "3 + 3" dose escalation design principle, subjects will be divided into 3 groups from low dose to high dose in sequence (Group A; Group B; Group C. Additional subjects will be enrolled into the RP2D group to ensure that 6-9 efficacy-evaluable subjects are available in the RP2D group before entering the phase II study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05050461 -
Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma
|
N/A | |
| Recruiting |
NCT06160362 -
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
|
N/A | |
| Recruiting |
NCT04435743 -
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas
|
||
| Recruiting |
NCT03720496 -
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy
|
Phase 1 | |
| Recruiting |
NCT06346912 -
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
|
Early Phase 1 | |
| Recruiting |
NCT05518383 -
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
|
Phase 4 | |
| Recruiting |
NCT02081937 -
CART-19 Immunotherapy in Mantle Cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06321289 -
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05909059 -
CAR T-cell Therapy in Patients With Renal Dysfunction
|
Phase 2 | |
| Recruiting |
NCT05631912 -
TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL
|
Phase 1/Phase 2 | |
| Completed |
NCT04094142 -
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05143112 -
Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04661020 -
CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT03497533 -
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04532268 -
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
|
Early Phase 1 | |
| Terminated |
NCT03488251 -
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04897477 -
Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06156774 -
SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
|